Allergy immunotherapy (AIT)

PreclinicalSmall molecule

Allergy immunotherapy (AIT) is one of 51 small molecule programs targeting Allergic Rhinitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic RhinitisActive, not recruiting

Eosinophilic EsophagitisActive, not recruiting

Allergic RhinitisPreclinical

Active, not recruiting

Eosinophilic EsophagitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

52 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Singulair

OOrganon and Co

Approved

13 2

Flovent

PParatek Pharmaceuticals Inc

Approved

12 3

Xyzal

CChattem

Approved

11 4

Alvesco

AAzurity Pharmaceuticals

Approved

8 5

Claritin

PPerrigo Company

Approved

6 6

Zyrtec

KKenvue Brands

Approved

5 7

Pulmicort

SSalix

Approved

5 8

Clarinex

OOrganon and Co

Approved

5 9

Qvar

SSchering-Plough

Approved

4 10

Allegra

CChattem

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergic Rhinitis1 trial

Impact of AIT on Allergic Rhinitis and Asthma

Completed·AALK-Abelló A/S··NCT04125888·92,048 enrolled

Eosinophilic Esophagitis1 trial

Allergy Immunotherapy in the Management of Eosinophilic Esophagitis

Withdrawn·UUnited States Naval Medical Center, San Diego·N/A·NCT01685034

Allergy1 trial

House Dust Mite Allergy Trial In Children

Completed·AALK-Abelló A/S·Phase 3·NCT04145219·1,460 enrolled

Unspecified1 trial

Intraseasonal Short-time Up-dosing With Alutard SQ Grasses

Completed·AALK-Abelló A/S·Phase 3·NCT00807547·149 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Allergy immunotherapy (AIT). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Allergy immunotherapy (AIT) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Allergy immunotherapy (AIT). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ALK-Abelló A/S company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AALK-Abelló A/S

Allergy immunotherapy (AIT)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Allergic Rhinitis1 trial

Eosinophilic Esophagitis1 trial

Allergy1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News